The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.
Shintaro Kanda
Honoraria - Sanofi
Yuichiro Ohe
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Hidehito Horinouchi
No relevant relationships to disclose
Yutaka Fujiwara
No relevant relationships to disclose
Hiroshi Nokihara
No relevant relationships to disclose
Noboru Yamamoto
No relevant relationships to disclose
Ikuo Sekine
No relevant relationships to disclose
Hideo Kunitoh
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi
Kaoru Kubota
Honoraria - AstraZeneca
Tomohide Tamura
Honoraria - AstraZeneca; Bristol-Myers Squibb; Sanofi